Topical Collagen Powder for Healing of Acute Full-thickness Wounds

NCT ID: NCT03481907

Last Updated: 2023-03-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-15
• Study Completion Date: 2018-11-01

Brief Summary

We have designed a pilot study to investigate the effect and potential utility of topical NuvagenTM (collagen powder) on the rate and quality of wound healing in healthy volunteers using the punch biopsy method. After inducing an acute full-thickness wound, the rate of complete healing of a wound treated with topical NuvagenTM (collagen powder) will be compared to the rate of complete healing of a wound treated with primary closure with sutures, the current gold standard. Qualification and semi-quantification of histologic and immunohistochemical markers will be used to assess the maturity and structural stability of the wound bed. Positive findings would suggest that NuvagenTM (collagen powder) may be capable of stimulating the healing of acute wounds in a similar or even superior manner to primary closure, suggesting collagen powder may be used in place of sutures, and encouraging further studies to characterize its therapeutic potential in dermatologic surgery.

Detailed Description

Each patient received a single 4mm punch biopsy on each anterior thigh to provide for internalized controls. One wound was managed with PC, while the other was treated with daily topical collagen powder for up to four weeks. Prior to each biopsy, the areas were cleansed with an alcohol swab and anesthetized using 1 mL of 2% lidocaine with epinephrine. An Integra Miltex 4.0 mm Standard Biopsy Punch instrument was used to create full-thickness wounds and pressure was applied with gauze until hemostasis occurred.

Up to one gram of topical type 1, 100% bovine collagen powder (NuvagenTM, CPN Biosciences, Inc., Largo, FL) was placed on one wound before covering it with a non-adherent sterile dressing. The other wound underwent PC with two epidermal sutures (Ethilon Nylon Sutures, Ethicon, Somerville, NJ) and was similarly covered with a sterile dressing. At the four week follow-up, wounds were re-biopsied following the same procedures.

For home treatment, patients were provided with collagen powder in one-gram containers and dressings along with the following instructions: 1) Irrigate the wound with tap water or saline solution, 2) Dry the wound with gently with dry gauze, 3) Apply up to one gram of collagen powder to the wound, and 4) Apply a sterile dressing. Assistance from a caregiver was permitted as needed. This procedure was repeated daily for four weeks after the first biopsy and until wound closure after the second biopsy. For wounds closed primarily, patients were instructed to apply petroleum jelly before covering the wounds with sterile dressings.

Conditions

Wound of Skin; Wound Heal

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Internalized Control

Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.

Group Type: OTHER

Nuvagen Collagen Powder

Intervention Type: DEVICE

Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding

Interventions

Nuvagen Collagen Powder

Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Outpatient, male or female subjects of any race, 18-75 years of age
• Able to understand the requirements of the study and understand and sign Informed Consent/HIPAA Authorization forms
• Patients willing to refrain from using topical medications to punch biopsy sites
• Patients who are willing to follow protocol instructions and return for follow-up visits

Exclusion Criteria

• Patients that have any medical or skin condition that could impair wound healing
• Patients that have used systemic medications that suppress the immune system within 5 half-lives (if known), or 2 months of enrollment (i.e. corticosteroids)
• Patients that have applied topical steroids to the thigh(s) in the 2 weeks prior to enrollment
• Patients that are currently participating in an investigational study of a drug or device or have participated within 4 weeks of enrollment
• Patients that in the opinion of the investigator demonstrate evidence of unwillingness or inability to follow instructions or to complete the study
• Patients currently using systemic antimicrobials
• Patients with a history of diabetes mellitus
• Patients with a history of bleeding disorders or concomitant treatment with aspirin or anticoagulants (including heparin, low molecular weight heparin, warfarin, fondaparinux, or rivaroxaban)
• Patients with a history of keloids or hypertrophic scars
• Patients with other conditions considered by the investigator to be reasons for disqualification that may jeopardize subject safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness)
• Patients with a known allergy or sensitivity to any component of the test medication (including bovine and/or collagen products) or local anesthetic agent used
• Current or previous users of tobacco products
• Recent alcohol or drug abuse is evident
• Pregnant females or nursing mothers. Eligible women of reproductive age will be required to have a negative urine pregnancy test at screening. They will also be required to be on at least 1 reliable form of effective birth control [examples: barrier method (condoms, diaphragm), oral, injectable, implant birth control or abstinence] during the course of this study and 30 days following the last treatment period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CPN Biosciences

INDUSTRY

Sponsor Role: collaborator

Adam Friedman

OTHER

Sponsor Role: lead

Responsible Party

Adam Friedman

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Adam Friedman, MD

Role: PRINCIPAL_INVESTIGATOR

GW School of Medicine and Health Sciences

Locations

George Washington Medical Faculty Associates

Washington D.C., District of Columbia, United States

Countries

United States

References

Qureshi A, Murphy E, Milando R, Rengifo-Pardo M, Clayton C, Friedman A. A Head-to-Head Comparison of Topical Collagen Powder to Primary Closure for Acute Full-Thickness Punch Biopsy-Induced Human Wounds: An Internally Controlled Pilot Study. J Drugs Dermatol. 2019 Jul 1;18(7):667-673.

Reference Type: DERIVED

PMID: 31334925 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

26552436

Identifier Type: -

Identifier Source: org_study_id